Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer

Vaccinex Inc VCNX shares are gaining after the Company reported interim response data in the Phase Ib segment of the KEYNOTE-B84 study.

  • The trial is evaluating Vaccinex's pepinemab combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
  • Among the three patients enrolled in the safety segment of the study, two patients experienced a complete response (CR). 
  • Biomarker analysis revealed that tumors in both responders expressed low levels of PD-L1 biomarker (CPS<20), a subset of HNSCC patients who have historically low response rates to anti-PD-1/L1 antibodies administered as single agents.
  • The investigator deemed the third patient in this group who had cancer of the tongue to have clinical progression and withdrew from the study at Week 6.
  • The study will enroll up to 65 subjects, with data readout anticipated in 2H of 2022
  • Price Action: VCNX shares are up 11.9% at $1.14 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!